Several small molecule inhibitors targeting CDK7 and CDK9 (such as fadraciclib, dinaciclib and BAY1143572) have been shown to inhibit MYCN transcription and selectively kill MYCN amplified or expressing neuroblastoma, medulloblastoma and other cancer cells and are currently in early phase clinical trial. The gene discussed is MYCN; the disease is neuroblastoma.